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Abstract  
Background  
Hypertensive disorders in pregnancy are common and their incidence appears to be on 
the increase. Preeclampsia is a multi-organ, heterogeneous disorder of pregnancy 
associated with significant maternal, fetal and neonatal morbidity and mortality. 
Because preeclampsia is a progressive disorder, invariably delivery remote from term is 
often necessary to halt disease progression to benefit the mother and fetus.   
 
Objectives  
 To determine the maternal outcomes in women with severe preeclampsia 
 To determine fetal and neonatal outcomes of infants born preterm 
 
Methods  
This was a prospective, descriptive study performed in three academic hospitals 
affiliated to the University of the Witwatersrand in Johannesburg. Data was collected 
from women with severe preeclampsia, who delivered between gestational ages of 26 
weeks and 33 weeks, with a minimum neonatal weight of 500g as determined by 
sonography.  
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Results  
In the sample of 92 patients enrolled, there were two maternal deaths as a result of 
severe preeclampsia. Eclampsia and HELLP syndrome were the most frequently 
observed maternal complications at 34% and 49% respectively. Caesarean section was 
the most frequent method used to expedite delivery in 84% of women. Of the 97 babies 
delivered, 20% were confirmed intra-uterine fetal deaths, 7% demised during the early 
neonatal period and a there was a 40% very low birth weight rate.  
Conclusion 
Despite interventions to reduce maternal and neonatal morbidity and mortality in our 
setting, our outcomes are similar to those observed in other parts of the world.  
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1. Introduction 
1.1 Background 
Despite advances in research into preeclampsia, a clear understanding of the 
processes preceding the development of this common and serious vascular 
complication of pregnancy has not yet been achieved. It is now well accepted that the 
proteinuria and hypertension of preeclampsia occur as a result of extensive endothelial 
dysfunction [1]. 
Hypertensive disorders of pregnancy are among the most common medical problems in 
pregnancy with an incidence of between 5-10% [2]. The incidence varies amongst 
different hospitals, regions and countries. Hypertensive disorders in pregnancy are a 
major cause of maternal and perinatal morbidity and mortality worldwide [3]. 
The clinical findings of preeclampsia can manifest as either a maternal syndrome 
(hypertension and proteinuria with or without other multi-organ involvement) or fetal 
syndrome (fetal growth restriction, oligohydramnios, abnormal umbilical artery Doppler 
findings and reduced placental growth with infarctions). Despite advances in perinatal 
care, the incidence of gestational hypertension-preeclampsia has not changed [4]. 
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1.2 Epidemiology  
Up to 10% of women have elevated blood pressures during their pregnancies [5].  
Three to eight percent of these women in developed countries develop preeclampsia [6, 
7] and up to 0.56 /1000 births are complicated by eclampsia [8].  Due to absence of 
epidemiological information in many low and middle income countries; lack of effort and 
capacity for data collection and reporting of vital statistics, the exact prevalence of 
preeclampsia and associated morbidity and mortality from low and middle income 
countries is unknown. However the World Health Organisation (WHO) estimates 
approximately 16% of maternal deaths in LMIC are due to hypertensive disorders   
pregnancy, of which eclampsia is the primary contributor [9]. The Saving Mothers 2008-
2010: Fifth report into Maternal Deaths in South Africa [10], reports that 14% of all 
maternal deaths in South Africa were due to hypertensive complications of pregnancy 
(chronic hypertension, preeclampsia, HELLP syndrome and rupture of the 
liver).Eclampsia was the major cause of death and accounted for 51.1% of the 
hypertensive deaths. There were 29.3% deaths from preeclampsia, 5% associated with 
chronic hypertension, 12.7% were due to HELLP syndrome and 1.3% related to rupture 
of the liver, while pulmonary oedema accounted for 27% of cases. Cerebral causes 
were the final cause of death in 51.1% of maternal deaths. 
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1.3 Risk Factors 
Several risk factors have been identified with an increased risk of preeclampsia. 
1.3.1 Familial Factors 
A familial history of preeclampsia increases the risk of preeclampsia substantially and 
women whose mothers had preeclampsia are more than likely to have preeclampsia 
[11]. Males who fathered a pregnancy complicated preeclampsia are more likely to 
father another pregnancy complicated by preeclampsia in another woman [12].  
1.3.2 Sperm Exposure 
Preeclampsia often affects young and nulliparous women, whereas older women are at 
greater risk for chronic hypertension with super imposed preeclampsia. Nulliparous 
women have a three-fold increased risk of developing preeclampsia as compared with 
multiparous women [13]. The primiparternity hypothesis suggests that the risks of 
preeclampsia are increased among women who have limited exposure to their partner’s 
sperm [14]. Data in support of this hypothesis includes lower risks of preeclampsia 
among multiparous women, among women who have had a previous pregnancy loss 
and following a prolonged pre-pregnancy conception and those who change partners. A 
prolonged birthing interval is the alternative explanation offered for the latter 
phenomenon [15], though the evidence for this observation has been disputed [16]. 
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1.3.3 Obesity  
Obesity is a definite risk factor for preeclampsia and the risk increases with a greater 
body mass index. Obesity has a strong link with insulin resistance, which is a risk factor 
for preeclampsia however; the exact mechanisms by which obesity and insulin 
resistance is associated with preeclampsia are poorly understood [17]. Possible 
explanations are increased shear vascular stress, associated with a hyper dynamic 
circulation; dyslipidaemia or enhanced cytokine mediated oxidative stress; amplified 
sympathetic activity and increased tubular sodium resorption;  and direct interference of 
insulin resistance and thus a  hyperinsulinaemic state with placentation. 
1.3.4 Co-morbid Conditions 
Women with gestational diabetes, insulin-dependent or non-insulin dependent diabetes 
and chronic hypertension are at higher risk of preeclampsia [23]. Studies have also 
shown that women with anti-phospholipid syndrome [18], thrombophilia, autoimmune 
disease, renal disease, and infertility [19] are at significantly higher risk of developing 
preeclampsia.   
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1.3.5 Smoking  
Numerous studies have shown that smoking reduces preeclampsia occurrence by 
approximately 50% in a dose-dependent manner [20]. This observation however has 
not been validated with snuff use. Women who are chronic smokers, those who smoke 
in early pregnancy and stop, do not have a reduced risk, whereas those who start 
smoking in late pregnancy and those who smoke throughout pregnancy are protected 
[21], however smoking is associated with unfavourable fetal outcomes in pregnancies 
complicated by preeclampsia. This data suggest that, although generally harmful in 
terms of pregnancy outcomes, the combustion products of tobacco have a protective 
effect in late pregnancy.  
1.3.6 Previous Preeclampsia 
Preeclampsia in a previous pregnancy is a strong predictor of preeclampsia in a 
subsequent pregnancy. The risk of recurrence is about 14% [24]. Odegard et al 
reported an even higher risk, with a 20 fold increase in preeclampsia risk compared with 
parous women with no previous preeclampsia [22]. In a large review of risk factors for 
preeclampsia, Duckitt and Harrington [23] reported a seven fold increased risk in 
women with previous preeclampsia compared with women without previous 
preeclampsia.  Interestingly the recurrence was inversely related to the gestational age 
at the initial confinement according to Mostello et al [24].  
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1.3.7 Heterogeneous Factors 
Extremes of age, multiple pregnancy and periodontal infections [25] have also been 
shown to increase the risk of preeclampsia. Chronic oral infections have been 
implicated as causative agents in variety of systemic illnesses including atherosclerotic 
cardiovascular disease and cerebrovascular ischaemia. Periodontal disease, a chronic 
gram negative infection has been associated with atherosclerosis, thromboembolic 
events and hypercholesterolemia [26-28]. Oral pathogens have been detected in 
atherosclerotic plaques, where they can play a role in the development and progression 
of atherosclerosis leading to coronary vascular disease [29]. Periodontal disease may 
provide a chronic burden of endotoxin and inflammatory cytokines, which serve to 
initiate and exacerbate atherogenesis and thrombogenesis. It is possible that the 
placenta may be similarly burdened in pregnant women who develop preeclampsia. 
In a matched case control study of 41 preeclamptic women and 41 normotensive 
healthy pregnant women, Canakci and colleagues found and an association between 
periodontal disease and risk of developing preeclampsia [30].  
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1.4 Definition of Hypertension in Pregnancy  
Normal pregnancy is characterised by a fall in blood pressure, detectable in the first 
trimester usually reaching a nadir in the second trimester. Blood pressure rises towards 
pre- conception levels towards the end of the third trimester. Hypertension in pregnancy 
is defined as a systolic blood pressure greater than or equal to (≥) 140 mmHg and a 
diastolic blood pressure greater or equal to (≥) 90 mmHg [31]. These readings should 
be confirmed by repeated readings over several hours. 
The classification of hypertensive disorders in pregnancy reflects the pathophysiology of 
the constituent conditions as well as the risks and potential outcomes for both mother 
and baby.  Several classification systems have been suggested over many years. The 
International Society for the Study of Hypertension in Pregnancy (ISSHP) has adopted 
the classifications proposed by the Australasian Society for the Study of Hypertension in 
Pregnancy (ASSHP) and the National High Blood Pressure Education Programme 
(NHBPEP) in the USA [31]. 
 
The classification is as follows: 
 Preeclampsia-eclampsia  
 Gestational hypertension 
 Chronic hypertension ( Essential or Chronic) 
 Preeclampsia superimposed on chronic hypertension 
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1.4.1 Diagnosis of Preeclampsia  
For purposes of this study we shall use the classification adopted by the ISSHP [31], the 
definitions of which are based on original work done by Davey and MacGillivray.  
Preeclampsia  
It is High Blood Pressure of 140/90mmHg or more on two separate occasions measured 
at least four hours apart, arising de novo after 20 weeks gestation in a woman with 
previously normal blood pressure accompanied by proteinuria, defined as urinary 
excretion of ≥300mg/24hrs. If 24-hour urine collection is not available, then proteinuria 
is defined as a concentration of at least 30mg/dl or at least 1+ on urinary dipstick [3].  
Severe Preeclampsia is accompanied by one of the following:  
 With the patient at rest, a blood pressure reading of at least 160 mmHg 
systolic or 110 mmHg diastolic, on two occasions at least four to six hours 
apart 
 Renal insufficiency as evidenced by a plasma creatinine of 90μmol/l and 
oliguria i.e. 400ml/24hrs 
 Liver disease ( elevated transaminases, severe right upper quadrant pain or 
epigastric pain with or without sub-capsular haematoma) 
 Neurological disturbances: severe headaches, persistent visual disturbances, 
hyper-reflexia with clonus and convulsion (eclampsia)  
 Haematological disturbances: thrombocytopenia, haemolysis and 
disseminated intravascular coagulation 
 Intra-uterine growth restriction. 
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Oedema is not included in the diagnostic criteria of preeclampsia. It is a common 
feature of normal pregnancy and severe preeclampsia may be present in the absence 
of any oedema. Nevertheless rapid development of generalised oedema should alert 
the clinician to screen for preeclampsia. Rarer disorders may present with some 
features of preeclampsia. Disorders such as acute fatty liver of pregnancy, haemolytic 
uraemic syndrome and thrombotic thrombocytopenic purpura may need to be excluded. 
Rarely preeclampsia presents before 20 weeks gestation, usually in the presence of a 
predisposing factors such as hydatidiform mole; multiple pregnancy, fetal triploidy and 
severe renal disease. 
1.4.2 Measuring Blood Pressure 
It is generally known that measurement of blood pressure is fraught with error. Mercury 
sphygmomanometry remains the gold standard; however this has largely been replaced 
by aneroid and automated machines. These machines, although easy to use, have 
inherent problems pertaining to validation. For example aneroid machines require 
calibration every 6 -12 months and their accuracy may deteriorate with time.  
According to the Working Group, the diastolic blood pressure is that at which the sound 
disappears (Korotkoff 5). In order to minimise inaccurate readings, an appropriate size 
cuff should be used (length 1.5 times upper arm circumference or a cuff with bladder 
encircling 80% or more of the arm) [31]. 
The pregnant patient should be seated, with feet supported for 2-3 minutes. Systolic 
blood pressure should be palpated at the brachial artery and cuff inflated to 20 mmHg 
above this level. The blood pressure cuff should be deflated slowly, at approximately 
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2mmHg per second. The systolic blood pressure is accepted as the first sound heard 
(K1) and diastolic as (K5). 
1.4.3 Proteinuria  
 
New onset proteinuria in pregnancy complicated by hypertension has formed the basis 
of the clinical diagnosis of preeclampsia for many years, and is included in all 
international guidelines; however the SOMANZ group does not define the necessity to 
have proteinuria to make the clinical diagnosis of preeclampsia. In non-gravid women, 
abnormal total protein is defined as protein excretion greater than 150mg/day. In normal 
pregnancy, urinary protein excretion increases substantially, secondary to increased 
glomerular filtration rate and increased permeability of the glomerular basement 
membrane. Hence a total protein excretion in excess of 300mg/day is considered 
abnormal in pregnancy.  
In most settings a dipstick is used to assess proteinuria, although inexpensive and 
commonly used, it has a significantly high false positive and false negative rate. 
Inaccuracies have also been identified with the 24 hour urine collection method, 
prompting use of alternative methods of measuring proteinuria in hypertensive 
pregnancies. The spot urine protein-creatinine ratio has been endorsed by both ISSHP 
[26] and NICE [32] as an acceptable method for assessment of proteinuria in 
pregnancy. A spot PCR cut off level of 30mg/mmol equates to a 24hr urine protein of ˃ 
300mg/day and has therefore been defined as significant in diagnosing preeclampsia.  
Current evidence suggests that the severity of proteinuria is not indicative of the severity 
of preeclampsia and thus should not be used to guide management. Although part of 
diagnostic criteria of preeclampsia, proteinuria may be absent. Data has shown that 
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10% of women with clinical manifestations of preeclampsia have no proteinuria and 
20% of eclamptic women do not have significant proteinuria prior to their eclamptic fit 
[33-41]. 
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1.5 Prediction of Preeclampsia 
Despite an intensive research effort to elucidate the origins of preeclampsia, there is 
currently no well validated effective method of identifying women at risk.  There are 
certain at-risk groups of patients such as those with chronic hypertension, pre-
gestational diabetes, multi-fetal gestations and previous pre-eclampsia. These patients 
account for the majority of cases of preeclampsia in multiparous women, yet only 
account for 14% of preeclampsia in nulliparous women. Thus, the majority of cases of 
preeclampsia arise from nulliparous women without medical complications.   
Prediction of risk will ideally identify patients for more careful monitoring but may also 
identify a population that is highly suited for research into aetiology of preeclampsia and 
for potential treatment and prevention. Many tests have been assessed for their relation 
to placental perfusion, vascular resistance, placental products, endothelial dysfunction, 
oxidative stress and fetal derived products. Of 27 tests reviewed by Meads and 
colleagues [42], only a few reached specifications above 90%.  These were BMI of 
34kg/m² or higher, α-fetoprotein and bilateral uterine artery Doppler notching. Sensitivity 
of higher than 60% was achieved only by uterine artery Doppler resistance index and 
combination of indices [43] 
Logistic regression analysis combining information on uterine artery pulsatility index, 
mean arterial pressures, serum PPAP-A, serum free PGF, BMI and presence of 
nulliparity or previous preeclampsia showed promising high sensitivity and specificity in 
prediction of early preeclampsia [44]. 
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1.6 Prevention   of preeclampsia 
Many therapeutic interventions have been trialled with a pattern of outcomes being 
similar, with initial small trials showing promising results followed by disappointing 
outcomes in larger studies. 
Prevention of a disease can either be primary, secondary or tertiary. Primary prevention 
implies avoiding the emergence of disease, secondary prevention entails halting the 
disease process prior to emergence of clinically recognisable disease and tertiary 
prevention means prevention of complications caused by the disease. 
 
1.6.1 Primary Prevention 
It has proved to be a monumental task to prevent emergence of preeclampsia. We now 
know that poor endovascular cytotrophoblast invasion of the spiral arteries; an 
exaggerated inflammatory response and inappropriate endothelial cell activation are 
instrumental in the pathogenesis of preeclampsia [45]. Therefore contraception is 
currently the most effective and reliable method of preventing preeclampsia in high risk 
patients. However numerous risk factors have been recognized, consequently 
manipulation of some of them may allow primary prevention. Obesity is a definite and a 
modifiable risk factor for developing preeclampsia and gestational hypertension. In a 
cohort study of 878 680 pregnancies, Conde-Agudelo and Belizan found that the 
frequency of preeclampsia for lean women (BMI<19.8) was 2.6% versus 10.1% in 
obese women (BMI>29.0) [46]. Although the exact mechanisms by which obesity is 
associated with an increase in preeclampsia are poorly understood, possible 
explanations are: increased shear stress due to hyper dynamic circulation associated 
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with obesity, dyslipidaemia or increased cytokine- mediated oxidative stress and direct 
haemodynamic effects of hyperinsulinaemia (increased tubular sodium resorption and 
increased sympathetic activity). Global increase in obesity is most likely causes a rise in 
the incidence of preeclampsia, thus prevention or effective treatment of obesity could 
result in a substantial decline in the frequency of preeclampsia. 
Cigarette smoking is associated with an approximate 30-40% decline in the risk of 
preeclampsia. Nevertheless, this benefit is negated by the adverse effects of smoking 
on the growing fetus, risk of an abruption and cardiovascular risks. An understanding of 
how smoking prevents preeclampsia could help unravel crucial aspects of its 
pathophysiology. 
1.6.2 Secondary Prevention 
Current strategies focus largely on pharmacological therapy, dietary interventions and 
lifestyle modification.       
I. Aspirin  
Inflammation plays an important role in the pathogenesis of preeclampsia; investigators 
have studied the role of aspirin in prevention and treatment of preeclampsia using this 
model. Alterations in the balance of thromboxane A2 and prostacyclin, along with 
platelet activation and endothelial dysfunction, provide the rational for aspirin use as a 
preventative modality. Duley et al. performed a meta-analysis of 59 randomised 
controlled trials, which included 37,560 women and reported on the effectiveness of 
anti-platelet agents in preventing preeclampsia [47]. It showed that anti-platelet agents 
reduced the risk of preeclampsia by 17% (RR 0.83; 95% CI 0.77-0.89), with 72 women 
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needing treatment to benefit one woman. While there was no statistical difference in 
relative risk (RR) based on maternal risks, there was a considerable increase in 
absolute risk reduction of preeclampsia for high risk compared to low risk women. In 
addition anti-platelet agents were associated with an 8% reduction in risk of preterm 
birth (29 trials, 31 151 women, RR 0.92, 95% CI 0.88 - 0.97); NNT 72. A further 14% 
reduction in fetal and neonatal death was noted from 40 trials, involving 33 098 women, 
RR 0.86, (95% CI 0.76 to 0.98); NNT 243. In addition, Duley and co-workers observed a 
10% reduction in small for gestational age babies in 36 trials, involving 23 638 women, 
RR 0.90, (95% CI 0.83 to 0.98).   
Commencing aspirin early in pregnancy was associated with a greater reduction in the 
incidence of preeclampsia than treatment beginning in later in pregnancy. The RR for 
preventing preeclampsia was 0.47 (95% CI 0.34 - 0.65) for aspirin started before 16 
weeks, and 0.81 (95% CI 0.63 - 1.03) started after 16 weeks of gestation [48]. Analysis 
of optimal dosage of the drug by the National Institute of Health and Clinical Excellence 
Guideline showed that 75mg of aspirin is the optimal dosage for prevention of 
preeclampsia - the increase in benefit was not observed for higher doses [32]. Current 
NICE Guidelines recommend high risk women take 75mg of aspirin daily from 12 weeks 
of gestation until birth of the baby.  
Other agents like nitric oxide donors, LMWH, progesterone, diuretics and anti-
hypertensive for mild and moderate hypertension have been considered however there 
is insufficient evidence to recommend their routine clinical use for prevention of 
preeclampsia. 
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II. Calcium  
Women with high intake of calcium have been observed to have a low incidence of 
hypertensive disorders of pregnancy [49]. This has led to the hypothesis that an 
increase in calcium intake might actually reduce the incidence of preeclampsia, 
especially in women with sub-optimal calcium intake. Calcium acts by reducing smooth 
muscle contractility and therefore vasoconstriction by its effect on the parathyroid gland 
and intracellular calcium. It might also have an indirect effect on smooth muscle function 
by increasing magnesium levels. Carroli et al have recently shown that calcium affects 
uteroplacental blood flow by reducing resistance in the uterine and umbilical vasculature 
[50].  
Hofmeyr et al. carried out a systematic review of 13 RCTs (15 730 women) and 
assessed the effectiveness of calcium supplementation in preventing preeclampsia [51]. 
Approximately two thirds of women had a low dietary calcium intake (10 678 women) 
and 587 women were at high risk of developing hypertensive disorders of pregnancy, 
i.e.  teenagers, women with previous preeclampsia, women with increased sensitivity to 
angiotensin two and women with pre-existing hypertension. Calcium was effective in 
preventing preeclampsia (RR 0.45; 95% CI 0.31 - 0.65). The beneficial effects were 
largely observed in the high risk group (RR 0.21; 95% CI 0.12 - 0.42) and in the group 
with low nutritional calcium intake (RR 0.36; 95% CI 0.20 - 0.65). The subgroup analysis 
of women with optimal dietary calcium intake showed no significant effect on the 
incidence of preeclampsia. A recommended daily dose of 1.5 to 2g of calcium reduces 
the incidence of preeclampsia in high risk women and women with low dietary calcium 
intake. 
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III. Anti-oxidants 
Data has shown that placental development in preeclampsia leads to reduced placental 
perfusion, and mediates a state of oxidative stress. Two naturally occurring anti-
oxidants (Vitamin C and E) may reduce such oxidation, thus protecting proteins and 
enzymes from destruction by free radicals.   
A systemic review by Rumbold et al. which included nine trials (5 446 women), 
evaluated the effectiveness of anti-oxidants for prevention of preeclampsia. No 
evidence was found to suggest that anti-oxidants prevent preeclampsia [52] 
IV. Marine oil  
Fish oils are a rich source of omega 3 fatty acids i.e. eicosapentaenoic acid and 
docosahexaenoic acid. These fatty acids are precursors of 3 series prostaglandins and 
have been shown to modulate inflammatory and vascular effects preeclampsia. Since 
preeclampsia and gestational hypertension are associated with vasoconstriction and 
endothelial damage, it is likely that marine oil fatty acids, especially eicosapentaenoic 
acid, can regulate these responses through direct competition with thromboxane A2 
precursor, arachidonic acid.  
Other agents such as evening primrose oil contain gamma linoleic acid which is a 
precursor of 1 series prostaglandins. These prostaglandins have the same mode of 
action as those derived from omega 3 fatty acids. 
In a meta-analysis by Makrides et al, six trials   involving 2783 were reviewed. Of the six 
randomised controlled trials, four (1683 women) comparing marine oil or evening 
primrose oil with placebo, did not show a reduction in preeclampsia [53].  The authors 
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concluded that evidence is lacking to support routine use of marine oil or evening 
primrose oil supplements during pregnancy to reduce the risk of preeclampsia.   
V. Lifestyle modification 
Preconception counselling in high risk women may offer the opportunity to optimise 
health. Women with diabetes and one factor of maternal vascular disease (diabetic 
retinopathy; diabetic nephropathy and pre-existing hypertension) have a 25% risk of 
developing preeclampsia and intra-uterine growth restriction (IUGR). Howarth et al 
reports that good glycaemic control modifies this risk [54]. Obesity is known to be a risk 
factor for both gestational hypertension and preeclampsia; in comparison with women of 
BMI 20-29.4; morbidly obese women (BMI>35) faced the highest risk of preeclampsia 
{Odds ratio (OR) 7.2} [55]. Weight loss in overweight and obese women before 
pregnancy may modify these risk factors including associated adverse outcomes. 
There is currently no evidence to demonstrate that lifestyle interventions, such as rest, 
exercise and dietary salt restriction prevent preeclampsia. 
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1.6.3 Tertiary prevention 
By far the most important part of tertiary prevention is without a doubt, proper antenatal 
care programmes. The aim of treating a pregnant woman is the prevention of 
complications. There is a consensus that drug treatment of severe hypertension is 
necessary and beneficial. The more concerning issues are the roles of pharmacological 
treatment for conservative management in severe preeclampsia aimed at prolongation 
of pregnancy, the ability of treatment to modify the course of the disease and the effect 
on fetal and maternal outcome [56].   The tertiary prevention of pre-eclampsia shall be 
addressed in the section on the management of the condition. 
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1.7 Management of severe preeclampsia 
Maternal and neonatal morbidity and mortality associated with hypertensive crises may 
have significant consequences. An important consideration is early involvement of 
senior obstetric and anaesthetic staff and experienced midwives in the assessment and 
management of women with severe preeclampsia. Up to 70% of all severely 
preeclamptic patients admitted to a critical care unit develop multi-organ dysfunction. 
Maternal complications associated with preeclampsia include eclampsia (<1%), HELLP 
syndrome (10-25%), acute kidney injury (AKI) (1-5%), pulmonary oedema (2-5%) and 
placental abruption (1-4%). The fetus may be small for gestational age with decreased 
fetal movements and decreased amniotic fluid volume. Severe preeclampsia is a 
significant risk factor for intrauterine fetal demise, with an estimated stillbirth rate of 
21/1000 [57]. Further, preterm delivery increases risks of neonatal death and serious 
morbidity from prematurity. 
 
The basic management objectives of pregnancy complicated by preeclampsia are: 
 Termination of pregnancy with the least possible trauma to the mother and 
fetus 
 Birth of an infant who subsequently thrives 
 Complete restoration of health to the mother 
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1.7.1. Antepartum management  
Initial assessment is aimed at classifying the severity of disease, the gestational age of 
the fetus and whether or not the patient is a candidate for expectant management. Once 
the diagnosis is made, the definitive treatment is delivery to prevent maternal or fetal 
complications from disease progression. The decision to deliver is based on gestational 
age, severity of the disease and maternal and fetal conditions. Evidence of severe 
maternal end-organ dysfunction or non-reassuring tests of fetal wellbeing are 
indications for prompt delivery irrespective of gestational age.  
Patients who are beyond 37 weeks gestation are delivered after stabilisation, however 
prior to term, the risks of adverse outcomes from disease progression need to be 
balanced against the risks of preterm birth. Alternatively, when the mother and fetus are 
stable and without complications, a conservative approach with close surveillance for 
evidence of disease progression is reasonable in order to gain fetal growth and lung 
maturity. 
On admission evaluation should include a full blood count (FBC), liver transaminases 
(AST and ALT), renal function (urea and creatinine), 24 hour urine collection or a spot 
protein creatinine ratio (PCR). Additional tests, where indicated, may include lactate 
dehydrogenase (LDH) level and a peripheral smear to exclude microangiopathic 
haemolysis and platelet destruction.   
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1.7.1.1. Blood pressure control 
Women with preeclampsia should be stabilised prior to delivery. It is important to take 
the blood pressure with a cuff of appropriate size. Korotkoff phase 5 is the appropriate 
measurement of diastolic blood pressure and manual aneroid sphygmomanometer is 
preferable.  
Targeting a systolic blood pressure (SBP) of <140-150mmHg and diastolic blood 
pressure (DBP) of 80-90mmHg minimises the risk of haemorrhagic stroke, as auto-
regulation is impaired when the mean arterial pressure (MAP) exceeds 145mmHg. 
Rapid reduction of SBP should be avoided; it may result in acute hypoperfusion and 
ischaemia of vital organs. Blood pressure should be checked every 15 minutes until the 
patient is stabilised. Most women can be managed with oral therapy alone, common 
therapeutic agents being labetalol, nifedipine, hydralazine and methyldopa.  
 
I.  Labetalol 
Labetalol is an alpha and beta adrenoceptor blocker with greater sensitivity for β 
receptors. It reduces blood pressure almost immediately, primarily by vasodilatation and 
reduction of heart rate at high doses. Unlike conventional vasodilators, it is not 
associated with maternal tachycardia and can be given orally or intravenously as an 
infusion. Compared to hydralazine, labetalol is as good as or more effective in reducing 
blood pressure [58] and does not affect uterine function. Labetalol should be avoided, if 
possible, in women with known asthma. Labetalol is an ideal drug when hypertension is 
associated with tachycardia or myocardial ischaemia. 
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II.  Nifedipine 
Nifedipine is a commonly used second-line antihypertensive agent and is a calcium 
channel blocker that results in vascular smooth muscle relaxation and vasodilatation. 
Only slow release preparations should be used. In particular, sublingual nifedipine may 
cause a precipitous drop in maternal blood pressure and thus should be avoided. Slow 
release nifedipine is used orally and blood pressure usually falls within 30 minutes of 
oral administration. 
III.  Methyldopa 
This drug is a centrally acting oral antihypertensive. Due to its good safety profile, it is 
often used as a first line antihypertensive agent. However studies have suggested 
superior benefits of labetalol over methyldopa. Occasionally, methyldopa is associated 
maternal transaminitis or a positive Coomb’s test.   
IV. Hydralazine 
Hydralazine acts directly on vascular smooth muscle to cause vasodilatation. Although 
evidence is not strong enough to preclude its use, it has largely been superseded by 
labetalol. Magee and colleagues conducted a meta-analysis of 21 trials (893); eight 
compared hydralazine with nifedipine, and five compared hydralazine with labetalol [59]. 
Hydralazine was associated with significantly higher maternal side effects and worse 
maternal and perinatal outcomes than either labetalol or nifedipine. 
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V. Angiotensin converting enzyme inhibitors  
ACE-1, when used in the second and third trimester, has been associated with renal 
dysfunction in the fetus, leading to oligohydramnios and anuria. ACE-I have also been 
associated with pulmonary hypoplasia, fetal growth restriction and hypoplasia of the 
fetal skull. Therefore this class of antihypertensive medication is absolutely 
contraindicated in pregnancy due to its teratogenic effects on the developing fetus.  
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1.7.1.2 Fluid management  
Pulmonary oedema is a common cause of maternal death, often being associated with 
inappropriate fluid management. Therefore accurate assessment of fluid balance is 
important to avoid iatrogenic pulmonary oedema. A systematic review by Duley et al. 
published in 2000; discourages fluid expansion and demonstrates that this confers good 
maternal outcomes [60]. Total fluids should be limited to 80ml/hr or 1ml/kg/hr. Urine 
output should be measured as part of input/output assessment and fluid restriction 
should be maintained until there is post-partum diuresis, at least 05ml-1ml/kg/hr. 
 
1.7.1.3 Thromboprophylaxis 
Preeclampsia is a significant risk factor for thrombosis, particularly in the presence of 
additional risk factors such as obesity, age above 35 years, previous thrombotic event, 
and family history of thrombosis, nephrotic range proteinuria and immobility in the ward. 
Antenatally, in labour and postnatally, all patients should have thromboprophylaxis in 
the form of graduated compression stockings, with or without low molecular weight 
heparin until they regain mobility. Heparin administration is not a contraindication to the 
insertion of an epidural catheter. However low molecular weight heparin should not be 
given until two hours after epidural anaesthesia and an epidural catheter should not be 
removed until 10 hours after the last dose, because of the risk of an epidural 
haematoma. 
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1.7.1.4 Fetal assessment  
After initial clinical assessment, fetal condition should include a non-stress test, 
umbilical artery Doppler waveform estimation, measurement of fetal growth and 
amniotic fluid volume index should be carried out. If immediate delivery is not imminent, 
and it is anticipated that there will be time for fetal benefit, antenatal corticosteroid 
should be administered regardless of a plan for expectant management. Randomised 
controlled trials involving pregnancies complicated by severe preeclampsia have found 
ante natal corticosteroid treatment to result in less respiratory distress syndrome (RR 
0.50; 95% CI 0.35-0.72), intra-ventricular haemorrhage (RR 0.38; CI 0.17-0.87) and 
neonatal death (RR 0.50; CI 0.29-0.87) [61].  
 
1.7.1.5. Timing of delivery 
The clinical course of severe preeclampsia is almost invariably a progressive 
deterioration in both maternal and fetal condition. Historically, a diagnosis of 
preeclampsia resulted in immediate delivery, either by induction of labour or caesarean 
section, to prevent further maternal morbidity and mortality. 
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Table 1 Maternal indication for expeditious delivery in severely preeclamptic 
women 
 
Uncontrolled severe hypertension (BP ≥ 160mmHg systolic or ≥ 110mmHg diastolic) 
despite maximum doses of at least two antihypertensive agents 
Eclampsia  
Pulmonary Edema  
Abruption placentae  
Oliguria (<0.5ml/kg/hr) that does not respond to fluid intake 
Imminent eclampsia 
HELLP syndrome with platelets < 100 000/µl 
Deteriorating renal function (serum creatinine ≥ 100µmol/l 
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Currently, in women with preterm severe preeclampsia the decision-making process 
has become slightly more complex and delivery may be delayed following assessment 
of maternal and fetal well-being, gestational age, and available supportive services for 
both mother and neonate. 
The only intervention known to date that can halt further progression of preeclampsia is 
delivery of both fetus and the placenta, as a result, delivery will always benefit the 
mother and rarely benefit the fetus. Most authorities agree that in the extremes of 
prematurity (24-30 weeks), if at all possible, delivery should be deferred at least long 
enough to administer corticosteroid therapy. 
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Table 2 Fetal indications for expeditious delivery in severe preeclamptic women 
 
Repetitive late decelerations 
Severe variable decelerations 
Decreased short term variability (<3 bpm) 
Biophysical profile ≤ 4on two occasions at least four hours apart 
Severe oligohydramnios  
 
Thus expectant management of severe preeclampsia may be considered in preterm 
pregnancies where the maternal condition is stable and fetal status is reassuring. 
However delivery is recommended in the presence of multi- organ dysfunction, fetal 
compromise or once a gestation of 32-34 weeks has been reached. 
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1.7.1.6. Role of Doppler Velocimetry  
The use of has been studied extensively in the IUGR fetus and patients with underlying 
medical diseases, in particular hypertensive disease of pregnancy. It is considered a 
primary tool for assessment of feto-maternal vascular status and management of 
pregnancy at risk of IUGR. Most of the work has been done in preterm pregnancies, 
with a focus on umbilical and middle cerebral arteries and the venous system. Absent or 
reverse flow in the umbilical artery is associated with approximately 60%-70% 
obliteration of placental arteries, rates of 50%-80% of intra-uterine hypoxemia, and an 
80-fold increased risk of perinatal mortality [62, 63, 64, 65, 66].  
Several meta-analyses have demonstrated that use of umbilical Doppler Velocimetry in 
conjunction with standard antenatal testing reduces the rate of fetal demise [67, 68, 69]. 
Through studies, such as those by Rizzo et al [70] and Hecher et al [71], it has become 
apparent that reverse venous flow in the ductus venosus and inferior vena cava during 
atrial contraction is most reflective of fetal metabolic acidosis. Several studies that have 
investigated venous Doppler changes and biophysical testing in severely growth 
restricted foetuses found that venous Doppler changes, especially ductus venosus, 
precede biophysical profile and fetal heart rate abnormalities. Thus it has been 
proposed that abnormal venous Doppler findings should be used to prompt delivery of 
the growth restricted fetus [72, 73, 74]. Doppler triggers for delivery, need to be 
reconciled with the gestational age, because gestational age is the strongest predictor 
of survival at least until 29 weeks’ gestation [73, 75]. Unfortunately, data regarding 
Doppler blood flow in pregnancies beyond 34 weeks gestation are limited for two 
reasons: (1) the overwhelming majority of fetal vascular Doppler studies have been 
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done on fetuses less than 34 weeks of gestation, and (2) umbilical artery Doppler is less 
reliable after 34 weeks. 
1.7.2 Intrapartum Management  
 
A diagnosis of preeclampsia should initiate two important management goals: 
 1. Control blood pressure and 
 2. Prevention of eclampsia. 
It is well established that treatment of severe hypertension will prevent cerebrovascular 
accidents and cardiovascular complications [2, 3]. Continuous maternal and fetal 
monitoring is indicated to identify worsening hypertension, deteriorating maternal 
hepatic, renal, cardiopulmonary, and neurological or haematological function as well as 
non-reassuring fetal heart traces.  
 
1.7.3 Prevention of convulsions  
Different therapies to prevent eclamptic convulsions in the setting of severe 
preeclampsia have been well studied. However, magnesium sulphate remains the drug 
of choice for seizure prophylaxis and for controlling seizures in eclampsia. The MAGPIE 
Trial in 2002 was a randomised, placebo-controlled trial that compared intravenous 
magnesium sulphate with placebo [76]. The study enrolled 10 141 women with 
preeclampsia from 33 countries and found that magnesium sulphate given as a 4g 
intravenous loading dose and 1g/hr maintenance dose significantly reduced the risk of 
eclampsia by half, thus reducing the risk of maternal death. Another study by Belfort et 
al. conducted in 2003 on 1650 women, which compared magnesium sulphate with 
nimodipine for seizure prophylaxis in women with severe preeclampsia, concluded that 
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magnesium sulphate was more effective than nimodipine (2.6% versus 0.8%, p=0.01) 
for seizure prophylaxis [77]. 
 A randomised controlled trial in 1995 of 2138 women compared phenytoin and 
magnesium sulphate for prevention of eclamptic convulsions in pregnant women with 
hypertension [78]. The results noted that 10 of 1098 women randomly assigned to 
phenytoin had eclamptic convulsions compared to none of the 1049 women assigned to 
magnesium sulphate. The study concluded that magnesium sulphate was superior to 
phenytoin when given prophylactically for eclamptic seizure for women with peripartum 
hypertension. A meta-analysis by Duley in 2010 reviewed 15 trials comparing 
magnesium sulphate and other anticonvulsants for women with preeclampsia. The 
meta-analysis concluded that magnesium sulphate was superior to placebo, phenytoin 
and nimodipine; in addition it more than halved the risk of eclampsia [79]. 
 
1.7.4 Anaesthetic considerations  
Whenever possible an anaesthetist should be informed about a woman with severe 
preeclampsia prior to labour or operative delivery, because appropriate anaesthetic 
management is associated with a reduction in both fetal and maternal morbidity and 
mortality [80].  
Relevant issues to be addressed include risk assessment, blood pressure control, fluid 
management, eclampsia prophylaxis and planning of a choice analgesia or anaesthesia 
[81, 82, 83] 
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1.8 Postpartum management  
During the immediate postpartum period, women with preeclampsia should receive 
close monitoring of blood pressure, symptoms consistent with severe disease and 
accurate measurements of fluid intake and output. Any laboratory test abnormalities or 
physical finding that has not returned to normal before post-delivery discharge should 
be reassessed at postpartum follow-up.  
The expectation is that hypertension and other signs or symptoms of organ dysfunction 
associated with preeclampsia will have remitted by the 6-week postpartum examination; 
if abnormalities persist, however, the patient should be re-examined again six weeks 
later, when any persisting pathological conditions will probably be chronic and 
appropriate referral should be made. 
1.8.1 Counselling regarding future pregnancies  
Women who experience pregnancies affected with hypertensive disorders have an 
increased risk of recurrence in subsequent pregnancies. The estimate of this risk was 
recently defined using the current definitions in a study from Finland of 895 women [84]. 
Depending on the diagnosis in the initial pregnancy, there is 58% to 94%recurrence risk 
of some type of hypertensive disorder in the second pregnancy. There is a higher risk of 
recurrence of hypertensive disorder in the next pregnancy if the diagnosis was made 
before 34-weeks of pregnancy, the patient is overweight or a significant weight gain 
between pregnancies. This will direct future counselling and impetus for a healthy 
lifestyle after pregnancy. 
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Thus it is advisable to counsel women at their 6-week postpartum visit about these 
future risks, to begin discussing the plan for maintaining a healthier diet and exercise 
habits as they had during pregnancy, and helping transition to a primary care provider 
who can further guide their interpregnancy health habits. Such patients should be 
advised to seek out a preconception consultation as well. To facilitate such 
consultations, the intra uterine devise is a great form of contraception as it requires a 
clinician visit for removal to become pregnant. 
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2. Problem Statement  
 
Preeclampsia, a human-specific disease is defined as the occurrence of hypertension 
and or proteinuria in a previously normal woman on or after 20th week of gestation; 
associated with significant maternal, fetal and neonatal morbidity and mortality. It is the 
most common medical complication of pregnancy whose incidence continues to 
increase both in South Africa and worldwide.  
Because preeclampsia is a progressive disorder, in some circumstances, delivery is a 
necessity to halt disease progression to benefit the mother and the fetus. However the 
need for premature delivery has adverse effects on important neonatal outcomes not 
limited to the most premature infants.  
The obstetrics protocol used in the Department of Obstetrics and Gynaecology of the 
University of the Witwatersrand is for management only. Outcomes have not previously 
been described for severe preeclampsia at gestations less than 34 weeks (remote from 
term), hence the need for this study.   
2.1. Objectives  
I. To determine outcomes of infants born preterm (26 weeks gestation to 34 
weeks gestation) to mothers with severe preeclampsia  
II. To determine maternal morbidity and mortality in women with severe 
preeclampsia 
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2.2 Methods  
2.2. 1 Setting  
The study took place at the three central referral hospitals affiliated to the University of 
the Witwatersrand namely: Charlotte Maxeke Johannesburg Academic Hospital, Chris 
Hani Baragwanath Academic Hospital and Rahima Moosa Mother and Child Hospital. 
 
2.2.2 Study Population 
The study recruited all women with severe preeclampsia between the 26 and 34 weeks 
of gestation or with a fetus weighing 500g or more on ultrasound assessment. 
Definitions, classifications and complications used were those adopted by the University 
of the Witwatersrand Department of Obstetrics and Gynaecology. 
 
2.2.3 Study Design and Data Collection 
This was a prospective, descriptive study of severely preeclamptic women presenting at 
3 three academic hospitals with pregnancies remote from term.  The study also followed 
up their babies for a period of three days during admission. All women were counselled 
prior to data collection and were invited to participate in the research. A consent form 
and an assent form in case of a minor were provided before data could be collected. 
Where maternal information was not readily available, it was obtained on admission and 
neonatal information was gathered from the neonatal ward and maternal registry book. 
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2.2.4 Sample Size  
All patients who met the criteria of severe preeclampsia and consented to participate 
were recruited into the study conducted over one calendar year: 01 June 2012 to 30 
June 2013.   During this time period 92 women were recruited. The sample size could 
potentially have been larger, however, some patients were missed as the data was not 
collected on consecutive days, Often patients declined to participate in the study and 
the most limiting factor was missing data which from maternity registry booklets. 
 
2.2.5 Inclusion criteria  
This study included women, who were diagnosed with severe preeclampsia, between 
26 weeks and 34 weeks of gestation at delivery.  
 
2.2.6 Data management 
An antenatal card provided the patient’s demographics, booking weight and height, 
blood pressure measurement, urine analysis, booking haemoglobin, rhesus status, 
syphilis and an HIV test result. At the clinics rapid test kits are generally used to test for 
syphilis and HIV. Blood pressure measurements at the three referral centres were 
obtained using an automated blood pressure machine. Blood pressure readings were 
routinely taken with patients in a supine position and urine protein estimation done using 
urinary dipstick. All bloods obtained for investigation were sent to the National Health 
Laboratory Service at the respective hospitals, where reference ranges for respective 
bloods have been standardised for the general population and pregnancy.  
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Laboratory variables 
Test  Reference Range  
Haemoglobin 12.1-16.3 g/dl 
Platelets  150-400*10^9/l 
Urea  2.1-7.1 mmol/l 
Creatinine 49-90 µmol.l 
AST 13-35 U/l 
ALT 7-35 U/l 
 
Data was entered into a Microsoft Excel spread sheet and then exported to the STATA 
11 statistical software package. Descriptive data were expressed as means with 
standard deviations, and medians with ranges.  
 
2.2.7 Ethics  
Ethics approval was granted by the University of the Witwatersrand ethics committee 
(HREC) and permission to access patients was granted by the CEOs of the three 
respective hospitals, consent forms attached in appendix section. 
 
2.2.8 Funding 
The study was funded by the researcher. 
2.3. Definitions used in the study (Adapted from Williams Obstetrics 23ed, 2011 
 Imminent eclampsia defined as acute hypertensive crisis, characterised by 
sudden rise in blood pressure, severe frontal headaches, visual disturbance and 
epigastric pain. 
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 HELLP syndrome is characterised by haemolysis, elevated liver enzymes, low 
platelets and haemolysis. In addition  AST≥70IU/L, platelet count less than 
100,000cells/ µl and characteristic schistocytes, also called helmet cells on a 
peripheral blood smear. 
 Proteinuria is defined as ≥ 0.3g of protein in a 24 hour urine specimen or a 
persistent 1+ (20mg/l) on dipstick or a random protein: creatinine ratio >0.3. 
Eclampsia defined as new onset of convulsions in women with either gestational 
hypertension or preeclampsia. 
 Placental abruption defined as premature separation of a normally situated 
placenta. It can either be concealed or revealed. 
 Disseminated intravascular coagulation defined as a pathological process 
produced by stimulation of coagulation activity, leading to consumption of clotting 
factors and platelets, leading to defective clotting. 
 Acute renal failure defines as an abrupt decrease in glomerular filtration rate, 
with serum creatinine of 100µmol/l, urea ≥ 5mmol/l and urine output less than 
400ml/24hours. 
 Stillbirth defined as a baby born dead after 28 weeks of intra- uterine life or with 
a mass of 1000g or more. 
 Neonatal death has 2 definitions: early neonatal death which occurs within six 
days of life and late neonatal death occurring from the seventh day of life up to 
twenty eight days from birth. 
 Birth asphyxia is a syndrome characterised by disturbed neurologic function in 
the earliest hours to days of life, manifested by: 
Severe Preeclampsia-Outcomes  Page 49 
 
  Apgar score of less than five  at five minutes and at ten minutes;  
 Fetal umbilical artery academia: fetal umbilical pH<7.0 or a base deficit 
≥12mmol/l and often  
 Accompanied by difficulty initiating and maintaining respiration, and by 
depression of tone and reflexes. 
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3. Results  
 
3.1 Demographic data 
Ninety-two women diagnosed with severe preeclampsia from 01 June 2012 to 31 May 
2013, having matched the inclusion criteria were recruited to the study and their records 
analysed.  Table 3 indicates age ranges of women with severe preeclampsia. The mean 
age for women was 29.5 ± 6.6 years. Sixty five women (70%) were below the age of 35, 
while twenty seven (30%) were of advanced maternal age. Eighty-five (92%) women 
were Black, four (4%) were Coloured and three (3%) were of Indian descent. 
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Table 3: Age ranges of women with severe preeclampsia (N=92) 
Range  Number (N) Percentage (%) 
15 -24 25 27% 
25 – 34 40 43 % 
>35 27 30 % 
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3.1 Maternal risk factors 
Table 4 outlines maternal risk factors related to preeclampsia. Over-all seventy five 
(81%) of women were booked either at local clinic or at the tertiary institutions.  Five 
(5%) women were known smokers, four (4%) reported occasional consumption of 
alcohol in the current pregnancy; however the volume consumed was not quantified. 
The mean gravidity of the women in the study was 2.4, with the highest gravidity being 
seven (1%).   A mean parity of 2.3 was observed.  Sixteen (17%) women were known 
chronic hypertensive patients on chronic anti-hypertensive medication, eighteen (19%) 
had a previous history of gestational hypertension and twenty five (27%) had 
preeclampsia in their previous pregnancies.  
Three (3%) were taking hypoglycaemic agents and five (5%) of the 92 women had twin 
pregnancies. Forty five patients (48.9%) had a family history of first degree relative with 
hypertension and of the 70 women who have previously been pregnant, fifty three 
(76%) were involved with same partner. for all  
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Table 4: Table of pregnancy-related risk factors on history  
Variable  Number (N) Percentage (%) 
Booking Status 75 81% 
Smoker  5 5% 
Alcohol  4 4% 
Twins  5 5% 
Chronic Hypertension  16 17% 
Gestational Hypertension 18 19% 
Previous Preeclampsia  25 27% 
Diabetes  3 3% 
*Partner  53 76%%% 
Family History  45 49% 
*Partner – is it the same partner for all pregnancies.   
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3.2 Gestational age of patients at diagnosis and delivery. 
Table 5.1 and 5.2 gives the gestational ages of patients at diagnosis and delivery. Of 
the 92 patients, 17 (18%) patients were un-booked; the mean booking gestational age 
was 19.8±6.54 weeks. The mean gestation at diagnosis was 29±2.67 weeks and the 
mean gestational age at delivery was 30±2.48 weeks. One patient was diagnosed with 
severe preeclampsia at 24 weeks and delivered at 30 weeks, while two patients were 
diagnosed 25 weeks delivered at 28 and 31 weeks respectively. 
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Table 5.1 Gestational at Diagnosis in weeks (N=92) 
Range  Frequency  Percentage (%) 
20 – 24 1 1 % 
25 -29 43 47 % 
30 -34 48 52 % 
 
 
Table 5.2 Gestational Age at Delivery in weeks (N=92) 
Range Frequency Percentage % 
25 -29 36 39 % 
30 -34 56 61 % 
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3.3 Antenatal booking blood results 
Of the 92 patients, 88 (95.6%) had booking haemoglobin results available. The booking 
Hb ranged from 6.0g/dl-16g/dl, with the mean Hb of 12±2.2g/dl. Not all patients 
consented to HIV testing in pregnancy, sixty one (66%) were HIV negative; twenty three 
(25%) were HIV positive and eight (9%) had an unknown while twenty two (96%) of the 
twenty three HIV positive patients were on anti-retroviral therapy. Table 6 gives the CD4 
count ranges of all HIV positive patients; the median CD4 count for the patients was 382 
cell/mm³ (IQR 184-549 cells/mm³). Six of the patients had CD4 counts less than 350 
cells/mm³ and seven patients had no record of their CD4 count. 
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Table 6 CD4 counts of HIV positive women in the study (N=16) 
Range Number (N) Percentage (%) 
100 -299 6 38 % 
300 – 499 5 31 % 
500 -699 3 19 % 
700 -899 2 12 %  
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe Preeclampsia-Outcomes  Page 58 
 
3.4 Body mass index distribution  
Table 7 gives the BMI of patients in the study. Of the 92 women in the study, 90 had 
their body weight and height recorded either at antenatal visit or on admission at the 
hospital. The mean body mass index was 30±6.2kg. Of note forty seven (52%) of the 
women in the study were obese as per the BMI. 
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Table 7 Body mass index (N=90) 
 BMI Ranges  Number(N) Percentage (%) 
Underweight  <18.5 kg/m² 1 1 % 
Normal  18.5 - 24.9 kg/m² 15 17 % 
Overweight  25 – 29.9 kg/m² 27 30 % 
Obese  > 30kg/m² 47 52 % 
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3.5 Blood pressure measurements  
On admission the patients’ blood pressures were recorded using automated machines. 
The mean SBP was 181±28 mmHg while the mean DBP was 112±16 mmHg. 
 
3.6 Biochemical findings 
Bloods taken on admission included haemoglobin (Hb); platelets; urea; creatinine; 
alanine transaminase (ALT) and aspartate transaminase (AST). The mean Hb was 
12±2 g/dl, the mean platelet count was 131±72; lowest platelet count was 31 and the 
highest count was 308. 
The mean urea was 5.7±3.7, 25% of patients had abnormal urea readings. Ninety-one 
patients had their creatinine levels recorded. The median creatinine was 71µmol/L (IQR 
71-96µmol/L) 
The ALT was recorded for 75 patients; the median ALT was 52U/L (IQR 23-111U/L) 
with AST available in 79 patients. The median AST was 61U/L (IQR 33-147U/L) 
All patients had proteinuria on urine dipsticks analysis; 74 (80%) patients received 
steroids for fetal lung maturity. 
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Table 8 Platelet count range (N=92) 
Platelet count  Number (N)  Percentage (%)  
< 50 000/µl 13 14% 
50 000 – 100 000/µl 20 21% 
100 000 – 150 000/µl 27 29% 
150 000 – 200 000/µl 15 17% 
250 000 – 300 000/µl 14 15% 
>300 000/µl 3 3% 
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3.7 Medication administered  
Figure 1 below depicts the antihypertensive medication administered; 83 (90%) patients 
received MgSO4 as prophylaxis and treatment, while 66 (72%) of patients received 
alpha methyldopa (AMD); 79 (86%) received nifedipine either as first line or as add on 
agent and 4 (4%) of patients needed labetalol for blood pressure control. 
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Figure 1 Antihypertensive drugs administered to women in the study (Y-axis = % 
of drugs given, X-axis = type of drug) 
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3.8 Decision to deliver 
Table 9 shows the indications for delivery in our study population. Fetal distress was the 
most frequently observed indication for delivery (40) 43%; HELLP syndrome accounted 
for (16) 18% followed by eclampsia (16) 17%. Placental insufficiency including IUGR 
accounted for (5) 5% of all indications for delivery and those who were imminently 
eclamptic accounted for 5% of deliveries. For patients who were diagnosed as 
imminently eclamptic, they were first stabilised, by means of blood pressure control, 
administration of magnesium sulphate at the same time corticosteroids were 
administered to improve fetal lung maturity. Once stabilised patients were delivered 
either for maternal reasons, that is worsening of symptoms and deterioration in fetal 
condition. 
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Table 9 Frequencies of Indications for Delivery (N=92) 
Indication  Patients (N) PERCENTAGE (%) 
 
Abruption  9 10 % 
ATN 1 2 % 
Eclampsia  16 17 % 
FD 40 43 % 
HELLP 16 18 % 
IE 5 5 % 
IUGR 5 5 % 
ATN, acute tubular necrosis; FD, fetal distress; HELLP, haemolysis elevated liver 
enzymes and low platelets; IE, imminent eclampsia, IUGR, intra uterine grown 
restriction. 
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3.9 Mode of delivery 
Of the 92 pregnancies; one patient with a placental abruption went into spontaneous 
labour, 77 (84%) were delivered by caesarean section and 14 (15%) had successful 
inductions of labour. 
3.10 Maternal outcomes 
Maternal outcomes are illustrated in Table 10. Two women 2 (2%) demised in the study 
and the maternal mortality ratio was 2:100 000 for this study. One had a massive intra-
cerebral bleed and the second patient demised from disseminated intravascular 
coagulation and renal failure. Most women in the study had more than one outcome, 45 
(49%) had HELLP syndrome; 31 (34%) had eclamptic seizures; 22 (24%) had acute 
kidney injury and 17 (18%) had placental abruptions. There were 3 (3%) ICU 
admissions two of which accounted for the mortalities observed, 3 (3%) had DIC, one 
which was mortality. 
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Table 10 Frequencies of Maternal Outcomes (N=92) 
Outcome  Frequency (N) Percentage (%) 
Abruption  17 18 % 
ARF 22 24 % 
CVA 1 1 % 
Death 2 2 % 
DIC 3 3 % 
Eclampsia 31 34 % 
HELLP 45 49 % 
ICU admission 3 3 % 
MMR 2:100 000  
ARF, acute renal failure; CVA, cerebrovascular accident; DIC, disseminated 
intravascular coagulation; MMR, maternal mortality rate 
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3.11 Neonatal outcomes  
Neonatal outcomes are shown in table 11.1 and table 11.2 respectively. Ninety two 
patients were analysed, of these 5 were twin pregnancies.  Seventy one (73%) babies 
had five minute Apgar scores of ≥6. There were 17 (19%) admissions to neonatal ICU 
and 49 (53%) were admitted to the neonatal unit. Fifteen (16%) patients had intrauterine 
fetal deaths; 6 (7%) had early neonatal deaths; 11 (12%) neonates had birth asphyxia; 
18 (20%) neonates had respiratory distress syndrome and 16 (17%) had intrauterine 
growth restriction. The median birth weight observed in the study was 1380 kg (IQR 
999-1800). 
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Table 11.1 Frequencies of Neonatal outcomes (N=97) 
Outcome  Number (N) Percentage % 
Admission  66 72 % 
Asphyxia  11 12 % 
ENND 6 7 % 
IUFD 15 16 % 
IUGR 16  17 % 
Hypoglycaemia  1 1 % 
Jaundice  3 3 % 
RDS 18 20 % 
NNMR 73/1000 
PNMR 216/1000 
ENND, early neonatal death; IUFD, intra-uterine fetal death, IUGR, intrauterine growth 
restriction, RDS, respiratory distress syndrome. 
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Neonatal birth weights are shown in table 11.2 (n=97). Eighty two (85%) of babies 
delivered weighed below two kilograms, while (15) 15% were above two kilograms. 
There were nine intra-uterine fetal deaths in the category less than a 1000g, three in the 
1000-1499 category and 3 between 1500-2499. 
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Table 11.2 Frequencies of birth weights born to women in the study 
Birth weight range Number (N) Percentage % 
500 – 999  24 25% 
1000 – 1499 33 34% 
1500 – 1999 25 26% 
2000 – 2499 14 14% 
>2500 1 1% 
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4. Discussion  
 
Severe preeclampsia that develops remote from term is associated with relatively higher 
rates of maternal morbidity and mortality as well as high perinatal morbidity and 
mortality. This study focused on a small cohort of women who developed severe 
preeclampsia before reaching term.  
 4.1 Demographic Data 
In this study most women with severe preeclampsia were between the age ranges of 
15-34 years (70%), mean age of 26.5±6.6 years, thus demonstrating that in this study, 
younger women were more affected by severe preeclampsia. This is in keeping with the 
studies by Jantasing and Tanawattanacharoen [61], where in their study the mean 
maternal age was 30.7±6.3 years and that of Moodley and Koranteng where their 
average age was 29±6.4 years [86]. 
Although we could not get a fair racial distribution, 85 (92%) of the patients were black; 
4 (4%) white and 3 (3%) were of Indian descent. Therefore we could not conclude that 
in our study there were racial disparities that could have influenced the outcomes. 
However Bryant et al. in their study found that blacks were more than likely to be 
diagnosed with preeclampsia (78 vs.53%, p=0.04) and more likely to have had systolic 
blood pressures more than 160 mmHg (43 vs. 17%, p=0.01) [87]. Among nulliparous 
women, black women have a risk of preeclampsia that is twice as high as that of white 
women. Similar results were also reported by Dempsey et al. who also found the risk in 
African-American women to be higher than in the Hispanic women [88].  
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The HIV prevalence in this study was 23%, which is slightly lower than the 29.5% rate 
which was reported by the National Antenatal Sentinel HIV Prevalence Survey of 2011, 
conducted among women attending state ante natal clinics [89]. Although the primary 
objective of this study was not to assess association of HIV with preeclampsia, a 
retrospective study in Soweto, by Frank et al, failed to show any association between 
HIV seropositivity and the risk of developing preeclampsia [90].  
4.2 Maternal risk factors  
Although preeclampsia is regarded as a disease of first pregnancy, the risk of 
preeclampsia increases in those with limited sperm exposure with the same partner 
prior to conception and a previous pregnancy with same partner is associated with 
reduced risk of preeclampsia, however this protective risk is lost with a change of 
partner. In this study more than two thirds of the patients were multiparous and more 
than half had a different partner in the index pregnancy. These findings however 
differed with those by Conde-Agudelo and Belizan, in which they found that nulliparity, 
was associated with an increased risk of preeclampsia [41].  
Previous history of hypertensive disease is a known risk factor for developing 
preeclampsia in pregnancy. Twenty seven percent of patients had a previous history of 
preeclampsia in this study; 20% had previous gestational hypertension and 17% were 
chronic hypertensive patients. Moodley et al. reported that a past history of hypertensive 
disease was present in 46% of their patients and that these patients had a greater fetal 
loss rate than those without a history of previous hypertensive disorder [86]. This study 
did not look at associations and therefore cannot confirm an increased risk. Although 
Severe Preeclampsia-Outcomes  Page 74 
 
maternal diabetes mellitus was only observed in 3% of patients, overwhelmingly, data 
proves that its presence substantially increases the risk of preeclampsia. 
Obesity and overweight are significant risk factors worldwide, contributing to an 
increased risk of cardiovascular disease, type 2 diabetes and reduced life expectancy. 
Basu et al. reported a prevalence of BMI of 28±5.9 in a South African pregnant 
adolescent population. Compared to their study, the incidence of obesity in our study 
was higher [91]. Of note we did not restrict our study to an adolescent population. 
Notably in our study, women who were overweight or obese were more likely to be 
diagnosed with preeclampsia. 
High maternal haemoglobin levels are generally associated with favourable maternal 
and perinatal outcomes. Although in this study it was not our objective to assess the 
association of haemoglobin level at booking with risk of preeclampsia, we had an 
average booking haemoglobin of 12±5.0. Murphy et al. showed that high levels of 
haemoglobin in the first and second trimester were related to adverse outcomes such 
as preeclampsia [92], while Dekker et al. suggested that serial measurements of 
haemoglobin and haematocrit could be used to monitor pregnancies at high risk of 
uteroplacental insufficiency [93]. Aghamohammadi A et al. in 2011 analysed 1008 
women from Iran, who booked before their 14th week of gestation, their study showed 
that the risk of developing pregnancy Induced hypertension was 2.46 times higher in 
women with Hb ≥ 13.2g/dl than in those with lower haemoglobin concentrations (11g/dl≤ 
Hb˂13.2g/dl)( OR=2.46, 95% CI : 1.0-6.1) [94].  
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4.3 Medication administered  
All women received antihypertensive medication as per institutional protocol. This study 
was a descriptive study, so no inferences could be made. about the effects of 
antihypertensive on the observed outcomes as all women in the study were delivered 
on emergency basis. 
Magnesium sulphate is the drug of choice to prevent convulsions in women with severe 
preeclampsia. In this study a significant number of women received MgSO4, 72% 
received MgSO4 as treatment for 24 hours post-delivery or as treatment of eclampsia 
while 17% received only a 4g loading dose of MgSO4 as prophylaxis. A study by Lee W 
et al. in 2004 on maternal and perinatal outcomes of eclampsia reported that 97% of 
their patients received magnesium sulphate. This practice is in keeping with current 
management of preeclamptic patients [95].  
 4.4 Maternal Outcomes  
The Report on Confidential Enquiries into Maternal Deaths in South Africa consistently 
reports preeclampsia as one of the leading five causes of maternal morbidity and 
mortality, while there was a 13.7% reduction in deaths due to complications of 
hypertension from the 2005-2007 report. The details relating maternal urinary, 
biochemical and haematological indices were recorded from the obstetric case records. 
Two deaths were recorded in this study, one from cerebrovascular accident and the 
other from disseminated intravascular coagulation. 
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All patients recruited in this study had at least one major morbidity, more than   the 30% 
reported by Moodley et al. in 1993 [86]. The most frequent complications were HELLP 
syndrome at 48% followed by eclampsia at 34%. The 18% incidence rate of abruption 
placentae was much higher than 4.3% incidence reported by Sibai [96] and the 9% 
incidence reported by Vigil-De Gracia [97] and similar to the 20% reported by Hall et al 
[98]. Interestingly in the very large series of expectant management of severe 
preeclampsia reported by Hall et al [98], the incidence of eclampsia was 1.2%, much 
lower than the 34% observed in our study. 
4.5 Fetal and neonatal outcomes 
The increased incidence of perinatal morbidity and mortality seen in pregnancies 
complicated by preeclampsia, although complex and multifactorial, is due to the need 
for premature delivery and uteroplacental insufficiency resulting in compromised blood 
supply to the fetus. In 1989 Derham et al, demonstrated that the most important factor 
in survival of a healthy neonate was gestational age, which was strongly related to birth 
weight at delivery [99]; in addition, in 1987 Odendaal et al. showed an increased 
perinatal survival as birth weight increased [100] and later Moodley et al. demonstrated 
in their study increased survival rates with increasing gestational age [86]. 
In this study the majority of intrauterine fetal deaths were due to maternal abruption, and 
although most patients received steroid therapy, the outcomes observed are purely 
related to prematurity.  
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5. Limitations 
 
The study was not without limitations. Due to the distances between the three hospitals 
data collection was not consistent and thus a larger sample could have been obtained 
for the time period undertaken. 
 Although most patients came in as emergencies, some patients were being managed 
conservatively thus when computing the data, that was not taken into account and may 
have led to a sampling bias, in addition the sample size was not large enough for this 
frequent and serious complication of pregnancy.  
The neonatal outcomes were strictly limited to the time the mom was hospitalised, thus 
data is lacking about long term outcomes of these infants.  
Another weakness of the study is that of limited information on the general population of 
Johannesburg - overwhelmingly most patients were black Africans, with limited 
contribution from other racial groups. 
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6. Conclusion  
 
This study thus confirms the manifestations of preeclampsia as a cause of both 
significant maternal and perinatal morbidity and mortality. We also found that a large 
number of the women had severe morbidity associated with severe preeclampsia and 
premature delivery is still the leading cause of perinatal morbidity and mortality. The 
differences with other studies may be attributed to the small number of patients 
recruited, racial differences, socioeconomic status and some certain demographic 
parameters such as parity and age. In addition some may be attributable to the fact that 
our hospitals serve as referral obstetric centres for extended number of primary care 
facilities of the surrounding semi urban areas. 
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APPENDIX A 
Patient Demographics 
Age __years 
Race B (1) C (2) I (3) W (4) O(5) 
 
Habits   
1. Smoker                    Y (1)                   N (0) 
 
Alcoholic                    Y (1)                   N (0) 
 
 
Obstetric History  
Parity   
Gravidity  
Chronic Hypertension Y (1)/N(0) 
Gestational Hypertension Y(1)/N(0) 
Severe Preeclampsia Y(1)/N(0) 
Diabetes  GDM(1)               IDDM(2)        NONE(0) 
Consort                   Same(1)             
Different(0)  
Family History( First Degree Relative)                     Y(1)                    N(0) 
 
Gestational Age  
At Booking __/40 
At Diagnosis  __/40 
At Delivery __/40 
 
Booking Parameters   
Hb __ g/dl 
RH +(1) / -(0)                      Unknown(2) 
RPR + (1) / - (0)                    Unknown(2) 
HIV +(1)  / -(0)                     Unknown(2)     
CD4 Count   
ART Y(1) N(0) 
Weight  __kg 
Height  __m 
BMI __kg/m2 
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Laboratory Data 
Full Blood Count HB  PLTS  
 
Urea & Creatinine only  U Cr    
 
Uric Acid  
ALT / AST ALT AST 
 
INR /PTT INR  PTT 
 
Protein Dipstick PCR 24HR 
Urine 
 
 
Treatment Options 
Alpha 
Methyldopa  
Y (1)  
N(0) 
Nifedipine Y(1)  N(0) 
Labetalol  Y(1)  N(0) 
Magnesium 
Sulphate  
Load (1) Load and maintain(2) None(0)  
Steroids  Single(1) Double(2) None(0) 
 
Decision to Deliver 
Fetal Distress 1 
Placental Insufficiency  (Doppler’s) 2 
Eclampsia  3 
HELLP Syndrome 4 
Renal Insufficiency 5 
Abruption  6 
Severe Oligohydramnios  7 
Imminent Eclampsia 8 
 
Mode of Delivery 
Induction of Labour 1 
Assisted Vaginal Delivery 2 
Caesarean Section 3                                         
Spontaneous Labour 4 
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 Outcomes  
Maternal  Y(1) N(0)  
Eclampsia   
Abruption   
HELLP Syndrome   
Acute Renal Failure  
DIC  
Intensive Care Unit Admission  
Cerebrovascular Accident   
Death  
Sub capsular  Haematoma  
Imminent Eclampsia  
Neonatal /Fetal : Y(1) N(0) 
Intra Uterine Death  Jaundice  
IUGR  IVH 
Birth Weight _____kg ENND 
5 minute APGARS____  
Birth Asphyxia   
Admission  NNU (1) NICU (2)  
RDS  
Necrotising Enterocolitis  
Hypoglycaemia   
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APPENDIX B 
Patient Information and Consent Form 
Hello. My name is Dr Thabane Poonyane. I am a doctor in this hospital (Baragwanath 
Hospital/ Rahima Moosa Hospital/ Charlotte Maxeke Johannesburg Academic Hospital). 
My main focus is helping women who might have specific problems relating to their 
pregnancies. I am trying to find out if we are doing enough for all pregnant women with 
severe blood pressure problems and what are the effects for both mother and the 
newborn. 
By taking part in this study you will be helping us to find better ways to help women with 
blood pressure conditions like yours and making sure their new-borns have the best 
care available. You will not be benefitting directly from this study, but what we find out 
about you may help others. 
To take part in this study all that you have to do is allow me to ask you a few questions 
and have access to your file and the baby’s information. Your identity is going to be 
concealed and only I will have access to it, all the information given to me will be 
protected at all times and nobody will have access to it. If you do not wish to have any 
part in the study your treatment here will not be affected in any way. You will still be 
appropriately treated for your hypertension, and so will your baby if he/she is not well. If 
you have decided to take part and then change your mind and withdraw from my study 
for any reason, there will be no ill-effects.  You will still receive the care you are entitled 
to. 
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In taking part in this study you will not have to experience any uncomfortable or painful 
procedures.  All I am interested in is what is documented in your file and what you have 
to say. If you decide to participate in this study the standard of care you will receive will 
be the same as all the patients in the ward and you will not be given anything in return 
e.g. food or money for your participation in the study.  
You can contact me at any time in connection with the study. My name is Dr Thabane 
Poonyane and my cell number is: 0826861340.If you are willing to be a participant in 
this study, kindly sign that you have understood all that has been explained to you and 
that you are a willing to take part in this study. 
 Patient name: ________________________________ 
Patient signature: ______________________________Date: 201__/__/___ 
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Parental Information and Assent Form 
Hello. My name is Dr Thabane Poonyane. I am a doctor in this hospital (Baragwanath 
Hospital/ Rahima Moosa Hospital/ Charlotte Maxeke Johannesburg Academic Hospital). 
My main focus is in helping women who might have specific problems relating to their 
pregnancies. I am trying to find out if we are doing enough for all pregnant women with 
severe blood pressure problems and what are the effects for both mother and the 
newborn. Your daughter has this condition. Because she is younger than 18 years we 
require your permission. 
By allowing her to take part in this study you will be helping us to find better ways to 
help women with blood pressure conditions like hers and making sure their newborn 
have the best care available. She will not be benefitting directly from this study, but what 
we find out about her may help others. 
To take part in this study, all that you have to do is allow me to ask you and your 
daughter a few questions and have access to her file and the baby’s information. Her 
identity is going to be concealed and only I will have access to it. All the information 
given to me will be protected at all times and nobody will have access to it. If you do not 
wish to have any part in the study your daughter’s treatment here will not be affected in 
any way. She will still be appropriately treated even if she decides not to take part and 
then changes her mind for any reason, there will be no ill-effects.  She will still receive 
the care she is entitled to. In taking part in this study she will not have to experience any 
uncomfortable or painful procedures. All I am interested in is what is documented in her 
file and what she has to say. 
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If you decide to allow her to participate in this study the standard of care she will receive 
will be the same as all the patients in the ward and she will not be given anything in 
return e.g. food or money for her participation in the study. You can contact me at any 
time in connection with the study. My name is Dr Thabane Poonyane and my cell 
number is: 0826861340. 
If you are willing to be a participant in this study, kindly sign that you have understood 
all that has been explained to you and that you are a willing to allow your daughter to 
take part in this study. 
 Patient name: ________________________________ 
Parent’s name: ________________________________ 
Parent’s signature: ______________________________ 
Date: 201__/___/___ 
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APPENDIX D 
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